

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

MYLAN PHARMACEUTICALS INC., TEVA PHARMACEUTICALS USA,
INC. and AKORN INC.,¹
Petitioners,

v.

ALLERGAN, INC.
Patent Owner.

Case IPR2016-01127 (US 8,685,930 B2)
Case IPR2016-01128 (US 8,629,111 B2)
Case IPR2016-01129 (US 8,642,556 B2)
Case IPR2016-01130 (US 8,633,162 B2)
Case IPR2016-01131 (US 8,648,048 B2)
Case IPR2016-01132 (US 9,248,191 B2)

**DECLARATION OF ANNA G. PHILLIPS IN SUPPORT OF
PETITIONER'S MOTION FOR *PRO HAC VICE* ADMISSION**

¹ Cases IPR2017-00576 and IPR2017-00594, IPR2017-00578 and IPR2017-00596, IPR2017-00579 and IPR2017-00598, IPR2017-00583 and IPR2017-00599, IPR2017-00585 and IPR2017-00600, and IPR2017-00586 and IPR2017-00601, have respectively been joined with the captioned proceedings. The word-for-word identical paper is filed in each proceeding identified in the caption pursuant to the Board's Scheduling Order (Paper 10).

MYLAN - EXHIBIT 1133

I, ANNA G. PHILLIPS, hereby declare the following:

1. I am a member in good standing of the state bars of Texas and California, as well as numerous United States District Courts and the United States Court of Appeals for the Federal Circuit.
2. I have not been suspended or disbarred from practice before any court or administrative body.
3. I have never had an application for admission to practice before any court or administrative body denied.
4. No sanction or contempt citation has been imposed against me by any court or administrative body.
5. I have read and will comply with the Office of Patent Trial Practice Guide and the Board's rules of Practice for Trials set forth in part 42 of the Code of Federal Regulations.
6. I will be subject to the USPTO Rules of Professional Conduct set forth in 37 C.F.R. §§ 11.101 et seq. and disciplinary jurisdiction under 37 C.F.R. § 11.19(a).
7. I am a patent litigation attorney with experience representing clients in a number of United States District Courts. I have experience in all stages of litigation, from preliminary injunction through trial and appeal, and across a wide range of technologies, including pharmaceutical drugs, formulations, and dosages. My biography is attached hereto as Exhibit A.

8. In a related matter involving the Patents-at-Issue,² I am representing Petitioner Mylan Pharmaceuticals Inc. in consolidated litigation currently pending in the Eastern District of Texas. *See Allergan, Inc. v. Teva Pharmaceuticals USA, Inc. et al.*, No. 2:15- cv-01455 (Lead Case). As a result, I have reviewed the Patents-at-Issue, their relevant file histories, and the prior art (including the prior art at issue in this *Inter Partes* Review proceeding). In addition, I have gained significant familiarity with claim construction issues pertaining to the Patents-at-Issue.

9. I have performed a detailed review of the Patents-at-Issue, the parties' submissions in the present *Inter Partes* Review proceeding, and the Board's Decision instituting *Inter Partes* Review of the Patents-at-Issue. Additionally, I have served an essential role in this *Inter Partes* Review proceeding, including working with the present Lead Counsel to prepare the Petitioner's Reply. Based on the foregoing, I have a detailed understanding of the Patents-at-Issue and the substantive and technical issues involved in this proceeding.

10. I am currently applying for leave to appear *pro hac vice* before the PTAB in the following related IPR proceedings: (1) IPR2016-01127; (2) IPR2016-01128; (3) IPR2016-01129; (4) IPR2016-01130; (5) IPR2016-01131; and (6) IPR2016-01132. I have not applied to appear *pro hac vice* in any other *Inter Partes* Review proceedings.

² The "Patents-at-Issue" are U.S. Patent Nos. 8,685,930 B2; 8,629,111 B2; 8,642,556 B2; 8,633,162 B2; 8,648,048 B2; 9,248,191 B2.

11. I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code.

Date: July 7, 2017

/ Anna G. Phillips /

Anna G. Phillips

EXHIBIT A

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.